Home › Core › ISCC-IDs › 28CrVzy1SD7Q7

View ISCC-ID

Core Data

28CrVzy1SD7Q7
ISCC-ID - digital asset identifier
CCd3KXcWFAqYF-CTfmfYeCo3vUB-CDKv43WG8A8r8-CRNrkrKgYw9mL
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

phase iii study of azacitidine and capecitabineoxaliplatin capox in refractory cimphigh metastatic colorectal cancer evaluation

Ledger Reference

coblo
Source Ledger/Blockchain
12406302
N-th ISCC Decleration on source ledger
49058bdd6cd6a9ffffef1474a07bda30b9e8e75fbf87cba2a1113b166676e1ff
Hash of block that includes the ISCC-DECLARATION
5d354bf3d865e6159edf28200dafd9c8d2c352240c1fc9da582413742a9b8d89
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Michael J. Overman", "@type": "Person"}, {"name": "Van Morris", "@type": "Person"}, {"name": "Helen Moinova", "@type": "Person"}, {"name": "Ganiraju Manyam", "@type": "Person"}, {"name": "Joe Ensor", "@type": "Person"}, {"name": "Michael S. Lee", "@type": "Person"}, {"name": "Cathy Eng", "@type": "Person"}, {"name": "Bryan Kee", "@type": "Person"}, {"name": "David Fogelman", "@type": "Person"}, {"name": "Rachna T. Shroff", "@type": "Person"}, {"name": "Thomas LaFramboise", "@type": "Person"}, {"name": "Thibault Mazard", "@type": "Person"}, {"name": "Tian Feng", "@type": "Person"}, {"name": "Stanley Hamilton", "@type": "Person"}, {"name": "Bradley Broom", "@type": "Person"}, {"name": "James Lutterbaugh", "@type": "Person"}, {"name": "Jean-Pierre Issa", "@type": "Person"}, {"name": "Sanford D. Markowitz", "@type": "Person"}, {"name": "Scott Kopetz", "@type": "Person"}], "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://hal.umontpellier.fr/hal-02298775/file/11317-171335-3-PB.pdf", "encodingFormat": "application/pdf"}, {"@type": "MediaObject", "contentUrl": "https://hal.umontpellier.fr/hal-02298775/document", "encodingFormat": "application/pdf"}], "publisher": {"name": "Impact Journals, LLC", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.18632/oncotarget.11317", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCd3KXcWFAqYF-CTfmfYeCo3vUB-CDKv43WG8A8r8-CRNrkrKgYw9mL", "propertyID": "ISCC"}], "datePublished": "2016-08-16"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close